Overview and Scope
Poly ADP-ribose polymerase (PARP) inhibitors are a class of pharmacological inhibitors that block the enzyme PARP, which is involved in deoxyribonucleic acid (DNA) repair. These inhibitors treat cancers with defects in other DNA repair pathways, preventing cancer cells from repairing damaged DNA and leading to their death.
Sizing and Forecast
The poly ADP-ribose polymerase (PARP) inhibitor market size has grown rapidly in recent years. It will grow from 7.52 billion in 2023 to $8.39 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to clinical research, regulatory approvals, market competition, drug combinations, and patient advocacy.
The poly ADP-ribose polymerase (PARP) inhibitor market size is expected to see rapid growth in the next few years. It will grow to $13.13 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to expanded indications, personalized medicine, biomarker development, health economics, and emerging markets. Major trends in the forecast period include precision medicine, immunotherapy advancements, targeted therapies, artificial intelligence in drug discovery, and patient-centric healthcare.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/poly-adp-ribose-polymerase-parp-inhibitor-global-market-report
Segmentation & Regional Insights
The poly ADP-ribose polymerase (PARP) inhibitor market covered in this report is segmented –
1) By Drug Type: Talazoparib, Veliparib, Olaparib, Other Drug Types
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Ovarian Cancer, Breast Cancer, Other Applications
4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15637&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of ovarian cancer is expected to propel the growth of the poly ADP-ribose polymerase (PARP) inhibitor market going forward. Ovarian cancer refers to a malignant tumor that develops in one or both of a woman’s ovaries, which are part of the female reproductive system responsible for producing eggs and female hormones. Ovarian cancer is growing due to impact of genetic predisposition, an aging population, environmental exposures, and hormonal imbalances. Poly ADP-Ribose Polymerase (PARP) Inhibitors are used in ovarian cancer treatment to target DNA repair mechanisms, specifically in patients with BRCA mutations, leading to synthetic lethality and enhanced tumor cell death. For instance, in February 2022, according to the World Ovarian Cancer Coalition, a Canada-based non-profit organization, ovarian cancer impacted 3.13 million women globally in 2020, and it’s projected to rise by 42% to reach 4.4 million by 2040. Further, over the same period, there’s expected to be a 51% surge in ovarian cancer-related deaths, climbing from 2.07 in 2020 to 3.13 in 2040. Therefore, the increasing prevalence of ovarian cancer is driving the growth of the poly ADP-ribose polymerase (PARP) inhibitor market.
Key Industry Players
Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc
The poly adp-ribose polymerase (parp) inhibitor market report table of contents includes:
1. Executive Summary
- Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Characteristics
- Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Trends And Strategies
- Poly ADP-Ribose Polymerase (PARP) Inhibitor Market – Macro Economic Scenario
- Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Size and Growth
…..
- Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Competitive Benchmarking
- Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Competitive Dashboard
- Key Mergers And Acquisitions In The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market
- Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Future Outlook and Potential Analysis
- Appendix
Explore the trending research reports from TBRC:
https://topprnews.com/gluten-feed-market
https://topprnews.com/organic-feed-market
https://topprnews.com/organic-pigments-market
https://goodprnews.com/rapeseed-oil-market
https://goodprnews.com/gluten-feed-market
https://goodprnews.com/manufactured-soil-market
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info
Healthcare Blog: https://healthcareresearchreports.com
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
